{
    "clinical_study": {
        "@rank": "100942", 
        "arm_group": [
            {
                "arm_group_label": "NeuroVax", 
                "arm_group_type": "Experimental", 
                "description": "NeuroVax"
            }, 
            {
                "arm_group_label": "IFA Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "IFA  Placebo"
            }
        ], 
        "brief_summary": {
            "textblock": "Multi-center, randomized , double-blind, placebo-controlled , two arm parallel design study\n      of NeuroVax\u2122 vs. Incomplete Freund's Adjuvant ( I F A) placebo. 200 subjects with Secondary\n      Progressive SPMS"
        }, 
        "brief_title": "A Study of NeuroVax\u2122, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis", 
        "completion_date": {
            "#text": "January 2017", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Secondary Progress Multiple Sclerosis", 
            "Multiple Sclerosis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Multiple Sclerosis", 
                "Sclerosis"
            ]
        }, 
        "detailed_description": {
            "textblock": "Objectives:The primary objective is to compare between treatment groups the cumulative\n      number of new gadolinium enhancing (Gd+) lesions on brain MRI at weeks 24, 32, 40 and 48 i n\n      subjects with secondary progressive MS. Secondary objectives include additional MRI\n      measurements, analyses of clinical relapses, measures of neurologic disability, immunologic\n      evaluations, and safety.\n\n      Study Design: Multi-center, randomized , double-blind, placebo-controlled , two arm parallel\n      design study of NeuroVax\u2122 vs. Incomplete Freund's Adjuvant ( I F A) placebo.\n\n      Subject Population: 200 subjects with Secondary Progressive SPMS MS, with an EDSS score >=\n      3.5 , and meeting all inclusion/exclusion criteria, will be enroll in this study. Subjects\n      will be randomized equally to NeuroVax\u2122 or I F A\n\n      ,1 0 0 per arm ."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Subject is between 18 and 50 years of age, inclusive.\n\n          -  Definite MS by the revised McDonald criteria (2005) (Appendix A), with a Secondary\n             Progressive course.\n\n          -  Expanded Disability Status Scale (EDSS) >=score 3.5 (Appendix B).\n\n          -  Two or more documented clinical relapses of MS in the preceding 24 months OR one\n             documented clinical relapse of MS in the preceding 1 2 months prior to screening .\n\n          -  Laboratory values within the following limits:\n\n               -  Creatinine 1 . 5 x high normal.\n\n               -  Hemoglobin"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "50 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "February 4, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02057159", 
            "org_study_id": "IR902-231"
        }, 
        "intervention": [
            {
                "arm_group_label": "NeuroVax", 
                "intervention_name": "NeuroVax", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "IFA Placebo", 
                "description": "IFA Placebo", 
                "intervention_name": "IFA Placebo", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Secondary Progress Multiple Sclerosis", 
            "SPMS", 
            "Multiple Sclerosis", 
            "NeuroVax"
        ], 
        "lastchanged_date": "February 7, 2014", 
        "link": [
            {
                "description": "Immune Response BioPharma,Inc.", 
                "url": "http://www.immuneresponse.net"
            }, 
            {
                "description": "Oregon Health & Science University", 
                "url": "http://www.ohsu.edu"
            }
        ], 
        "location": {
            "contact": {
                "last_name": "Dennis Bourdette, F.A.A.N. M.D.", 
                "phone": "504-494-7772"
            }, 
            "facility": {
                "address": {
                    "city": "Portland", 
                    "country": "United States", 
                    "state": "Oregon", 
                    "zip": "97239"
                }, 
                "name": "Multiple Sclerosis Center Oregon Health & Science University"
            }, 
            "investigator": {
                "last_name": "Dennis Bourdette, F.A.A.N. M.D.", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase II Study of NeuroVax\u2122, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis", 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "July 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "The primary objective is to compare between treatment groups the cumulative number of new gadolinium enhancing (Gd+) lesions on brain MRI at up to 48  weeks  in subjects with secondary progressive MS", 
            "safety_issue": "Yes", 
            "time_frame": "up to 48 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02057159"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Secondary MRI measurements", 
                "measure": "Secondary MRI measurements objectives include additional MRI measurements, analyses of clinical relapses, measures of neurologic disability, immunologic evaluations, and safety.", 
                "safety_issue": "Yes", 
                "time_frame": "48 Weeks"
            }, 
            {
                "description": "Analyses of clinical relapses", 
                "measure": "Analyses of clinical relapses", 
                "safety_issue": "Yes", 
                "time_frame": "48 Weeks"
            }, 
            {
                "description": "Measures of neurologic disability EDSS score", 
                "measure": "Measures of neurologic disability EDSS score", 
                "safety_issue": "Yes", 
                "time_frame": "48 Weeks"
            }, 
            {
                "description": "Immunologic evaluations", 
                "measure": "Immunologic evaluations", 
                "safety_issue": "Yes", 
                "time_frame": "48 Weeks"
            }, 
            {
                "description": "Safety", 
                "measure": "Safety", 
                "safety_issue": "Yes", 
                "time_frame": "48 Weeks"
            }
        ], 
        "source": "Immune Response BioPharma, Inc.", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "PPD", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Oregon Health and Science University", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Immune Response BioPharma, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2015", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}